Etoposide Injection

This product is a cell cycle-specific anti-tumor drug that acts on DNA topoisomerase II to form a stable reversible complex of drug-enzyme-DNA, which hinders DNA repair. Experiments have found that this complex can be reversed with the elimination of the drug, allowing the damaged DNA to be repaired and reducing cytotoxicity. Therefore, extending the drug administration time may increase the anti-tumor activity.

Active ingredient: Etoposide.

It is mainly used to treat small cell lung cancer, malignant lymphoma, malignant germ cell tumor, leukemia, and has certain therapeutic effects on neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer and esophageal cancer.

Intravenous drip. Dilute the required amount of this product with sodium chloride injection, the concentration per milliliter should not exceed 0.25mg, and the intravenous drip time should be no less than 30 minutes. Solid tumors: 60 to 100mg/m2 per day, for 3 to 5 consecutive days, and repeat the medication every 3 to 4 weeks. Leukemia: 60 to 100mg/m2 per day, for 5 consecutive days, and repeat the medication at regular intervals according to the blood picture. Common dosage for children: intravenous drip per day, 100 to 150mg/m2 per body surface area, for 3 to 4 consecutive days.

Common adverse reactions include hair loss, loss of appetite, nausea, vomiting, palpitations, dizziness, hypotension, phlebitis and bone marrow suppression.

1. It is contraindicated for patients with bone marrow suppression, or significantly low white blood cells and platelets; 2. It is contraindicated for patients with severe heart, liver and kidney dysfunction; 3. It is contraindicated for pregnant women.

Precautions during pregnancy and lactation: Contraindicated for use during pregnancy.

1. Because this product has a significant bone marrow suppression effect, it should be used with caution when used in combination with other anti-tumor drugs. 2. This product can inhibit the body's immune defense mechanism, so that vaccination cannot stimulate the production of human antibodies. 3. Virus vaccines should not be administered within 3 months after the end of chemotherapy. 4. This product has a high binding rate with plasma proteins. Therefore, the combined use of drugs that bind to other plasma proteins may affect the excretion of this product.

Keep away from light and sealed.

5ml:0.1g

Langzhi Group Wanrong Pharmaceutical Co., Ltd.

• Founded in:

  2002-07-10

• Address:

  No. 99, Xinjian South Road, Wanrong County, Shanxi Province

• Tax NO.:

  91140822739343626G

• Registered Funds:

  5 million yuan

• Website:

  Log in to view

• Email:

  Log in to view